Trial reportCritical care (London, England)2025
Cardiovascular effects of lactate in healthy adults.
Trial report in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04710875 (The Role of Lactate in Lipolysis and Catabolism in Humans), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Lactate in Lipolysis and Catabolism in Humans
Who cites it
9 citing papers in PubMed.
- Not racemic after all: stereochemical composition of a commercially available sodium lactate solution.Critical care (London, England) · 2026Article
- Lactate in cardiogenic shock: pathophysiology, prognostic value, and clinical interpretation.Annals of intensive care · 2026Review
- Functional and muscle recovery after critical illness: current and future nutritional, physical and metabolic strategies.Annals of intensive care · 2026Review
- Cardiovascular effects of hypertonic lactate solutions: acid-base or metabolic cause, or both? Authors' reply.Critical care (London, England) · 2025Article
- Cardiovascular effects of hypertonic lactate solutions: acid-base or metabolic cause, or both?Critical care (London, England) · 2025Article
- Cardiovascular effects of lactate in healthy adults: D-lactate, the forgotten enantiomer-authors' reply.Critical care (London, England) · 2025Article
- Lactate, an Essential Metabolic Marker in the Diagnosis and Management of Pediatric Conditions.Diagnostics (Basel, Switzerland) · 2025Review
- Cardiovascular effects of lactate in healthy adults: D-lactate, the forgotten enantiomer.Critical care (London, England) · 2025Article
- Lactate infusion improves cardiac function in a porcine model of ischemic cardiogenic shock.Critical care (London, England) · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
backgroundLow-volume hypertonic solutions, such as half-molar lactate (LAC), may be a potential treatment used for fluid resuscitation. This study aimed to evaluate the underlying cardiovascular effects and mechanisms of LAC infusion compared to sodium-matched hypertonic sodium chloride (SAL).
methodsEight healthy male participants were randomized in a controlled, single-blinded, crossover study. Each participant received a four-hour infusion of LAC and SAL in a randomized order. Assessor-blinded echocardiography and blood samples were performed. The primary endpoint was cardiac output (CO) measured by echocardiography.
resultsDuring LAC infusion, circulating lactate levels increased by 1.9 mmol/L (95% CI 1.8-2.0 mmol/L, P < 0.001) compared with SAL. CO increased by 1.0 L/min (95% CI 0.5-1.4 L/min, P < 0.001), driven primarily by a significant increase in stroke volume of 11 mL (95% CI 4-17 mL, P = 0.002), with no significant change in heart rate. Additionally, left ventricular ejection fraction improved by 5 percentage points (P < 0.001) and global longitudinal strain by 1.5 percentage points (P < 0.001). Preload indicators were elevated during SAL infusion compared with LAC infusion. Concomitantly, afterload parameters, including systemic vascular resistance and effective arterial elastance, were significantly decreased with LAC infusion compared with SAL, while mean arterial pressure remained similar. Indicators of contractility improved during LAC infusion.
conclusionsIn healthy participants, LAC infusion enhanced cardiac function, evidenced by increases in CO, stroke volume, and left ventricular ejection fraction compared with SAL. Indicators of contractility improved, afterload decreased, and preload remained stable. Therefore, LAC infusion may be an advantageous resuscitation fluid, particularly in patients with cardiac dysfunction. CLINICAL TRIAL REGISTRATIONS: https://clinicaltrials.gov/ct2/show/NCT04710875 . Registered 1 December 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.